These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36493981)

  • 1. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
    Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
    J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
    Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
    Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
    Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
    Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
    Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
    Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
    Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
    Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer.
    Dolan RD; Laird BJA; Klepstad P; Kaasa S; Horgan PG; Paulsen Ø; McMillan DC
    Medicine (Baltimore); 2019 Sep; 98(37):e17019. PubMed ID: 31517821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
    Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
    Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
    [No Abstract]   [Full Text] [Related]  

  • 8. The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer.
    Dolan RD; Daly LE; Simmons CP; Ryan AM; Sim WM; Fallon M; Power DG; Wilcock A; Maddocks M; Bennett MI; Usborne C; Laird BJ; McMillan DC
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
    Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
    Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer.
    Takamizawa Y; Shida D; Boku N; Nakamura Y; Ahiko Y; Yoshida T; Tanabe T; Takashima A; Kanemitsu Y
    BMC Cancer; 2020 Nov; 20(1):1092. PubMed ID: 33176752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
    Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.
    Minami S; Ihara S; Kim SH; Yamamoto S; Komuta K
    World J Oncol; 2018 Feb; 9(1):13-20. PubMed ID: 29581811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
    Pantano Nde P; Paiva BS; Hui D; Paiva CE
    J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
    Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
    Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score-matched analysis.
    Cui C; Wu X; Deng L; Wang W; Cui W; Wang Y
    Thorac Cancer; 2022 Jul; 13(14):2041-2049. PubMed ID: 35624549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.